Evidence map›Paper›PMID 18184860›Full record

ArticleJournal of the American Society of Nephrology : JASN2008

PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis.

Frank Eitner, Eva Bücher, Claudia van Roeyen, Uta Kunter, Song Rong, Claudia Seikrit, Luigi Villa, Peter Boor, Linda Fredriksson, Gudrun Bäckström and 4 more

Abstract read
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
8.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 1 synthesis or guideline pooled it, 120 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Frontiers in pharmacology · 2024
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Anti-angiogenic properties of microRNA-29a in preclinical ocular models.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  20. Targeting fibrosis, mechanisms and cilinical trials.Signal transduction and targeted therapy · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Frank EitnerDivision of Nephrology and Immunology, Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany. feitner@ukaachen.de
Eva Bücher
Claudia van Roeyen
Uta Kunter
Song Rong
Claudia Seikrit
Luigi Villa
Peter Boor
Linda Fredriksson
Gudrun Bäckström
Ulf Eriksson
Arne Ostman
Jürgen Floege
Tammo Ostendorf
RWTH Aachen University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsAntibodiesCells, CulturedChemokine CCL2FibroblastsFibrosisKidneyLymphokinesMacrophagesMaleMiceMice, Inbred C57BLMice, Mutant StrainsMonocytesNephritis, InterstitialNeutrophilsAntibodiesCcl2 protein, mouseChemokine CCL2LymphokinesPlatelet-Derived Growth Factorplatelet-derived growth factor CReceptors, Platelet-Derived Growth Factor

Identifiers

PMID18184860
PMCPMC2396746
OpenAlexW1988760910

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.